MASI Stock Drops Despite Strong Q2 Results and Rising Margins

Strong Performance in Q2 2025

Masimo Corporation delivered impressive results for the second quarter of 2025, with adjusted earnings per share (EPS) reaching $1.33, a significant increase of 46.2% compared to the same period last year. This figure surpassed the Zacks Consensus Estimate by 8.1%, highlighting the company’s strong financial position.

The adjustments made to arrive at this EPS figure included factors such as acquired intangible asset amortization and costs related to acquisitions, integrations, and divestitures. On a GAAP basis, the EPS for the quarter was 82 cents, up 78.3% from the 46 cents recorded in the second quarter of 2024.

Revenue Growth and Performance

Masimo reported total revenues of $370.9 million for the second quarter, marking a 7.9% increase year over year on a reported basis. This performance slightly exceeded the Zacks Consensus Estimate by 0.6%. When adjusted for constant exchange rates (CER), revenues were $370.3 million, representing a 7.4% growth compared to the previous year.

According to management, the revenue growth was driven by increased sales of consumables, which partially offset a decline in capital sales. The shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 63,100 units during the quarter, showing a 7.7% year-over-year increase.

Despite these positive figures, shares of Masimo fell nearly 2.7% in after-hours trading, indicating some market uncertainty.

Segmental Breakdown

Masimo's revenue came from two primary sources: revenue excluding related party revenues and related party revenues. Revenue excluding related party revenues reached $345.1 million, a rise of 8.2% year over year. Related party revenues amounted to $25.8 million, reflecting a 2.8% increase.

The company's revenue was segmented into Healthcare and Other. Healthcare revenues totaled $370.3 million, an increase of 7.7% on a reported basis and 7.4% at CER. Within the Healthcare segment, consumable and service revenues grew by 8.4%, while capital equipment and other revenues declined by 2%.

Other revenues for the quarter were $0.6 million, slightly below the projected $1 million.

Margin Analysis

Masimo’s gross profit for the quarter rose 12.5% year over year to $233.3 million, with a gross margin expanding by 262 basis points (bps) to 62.9%. This outperformed the projected gross margin of 63.2%.

Selling, general, and administrative expenses increased by 9.9% year over year to $138.9 million. However, research and development expenses decreased by 23.5% to $29.9 million. Total adjusted operating expenses of $168.8 million saw a 2.1% increase.

Adjusted operating profit for the quarter reached $64.5 million, a 53.9% increase from the prior year. The adjusted operating margin expanded by 521 bps to 17.4%, reflecting improved efficiency.

Financial Position and Guidance

At the end of the second quarter of 2025, Masimo had cash and cash equivalents of $149.6 million, up from $130.8 million at the end of the first quarter. Long-term debt stood at $598.7 million, compared to $636 million at the end of the previous quarter.

Cumulative net cash provided by operating activities from continuing operations was $99.5 million, down slightly from $106 million a year ago.

Masimo has raised its 2025 revenue guidance, projecting total revenues between $1,505 million and $1,535 million, reflecting an 8-11% increase at CER from the comparable 2024 period. Adjusted EPS for 2025 is now expected to range between $5.45 and $5.70, up from the previous outlook of $5.30 to $5.60.

Outlook and Market Position

Masimo ended the second quarter of 2025 with strong top and bottom-line performance, driven by growth in healthcare revenues and improved margins. The continued strength in consumable and service revenues is promising, and the expansion of both gross and operating margins suggests positive future prospects.

On the earnings call, management indicated efforts to mitigate the impact of tariffs, which adds to investor optimism. However, the decline in capital equipment and other revenues remains a concern.

Comparison with Industry Peers

Masimo currently holds a Zacks Rank of #3 (Hold). In the broader medical space, several better-ranked stocks have also announced quarterly results:

• GE HealthCare Technologies Inc. (GEHC): Carries a Zacks Rank of #1 (Strong Buy), with adjusted EPS of $1.06, surpassing estimates by 16.5%.
• West Pharmaceutical Services, Inc. (WST): Holds a Zacks Rank of #1, with adjusted EPS of $1.84, exceeding estimates by 21.9%.
• Boston Scientific Corporation (BSX): Has a Zacks Rank of #2 (Buy), with adjusted EPS of 75 cents, beating estimates by 4.2%.

These companies demonstrate strong performance and are considered favorable investment options in the current market.